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Abstract
Background: Breathing retraining techniques have received increased attention in the management of asthma,
because there is growing evidence of the usefulness of such methods in improving quality of life, reducing
symptoms and reducing bronchodilator use. Our study investigated the effect of anthroposophic therapeutic
speech (ATS), which uses sounds and syllabic rhythm to improve articulation, breathing and cardiorespiratory
interaction, in patients with asthma in a real-life outpatient setting.
Methods: In a randomised controlled crossover trial, patients with asthma in three centres in Switzerland and
Germany were randomised to either receive 11 ATS sessions or to wait. Subsequently, patients changed either to
wait or to receive ATS. Primary outcomes were changes from the beginning to the end of each phase in the
Asthma Quality of Life Questionnaire (AQLQ) and spirometry parameters. Secondary outcomes were changes in
inhaled glucocorticoids, the Asthma Control Test (ACT), peak flow and asthma exacerbations.
Results: Altogether, 63 patients were randomised, of which 56 were enrolled and 49 completed the study. Statistically
significant differences between the ATS groups and waiting control groups were found for the overall AQLQ score
(d = 0.86, p = 0.001) and the domain scores for symptoms, activity limitation and emotional function as well as ACT
score (d = 0.53, p = 0.048). No significant differences were observed in spirometry parameters, inhaled glucocorticoids,
peak flow and days without asthma exacerbation per week. No serious adverse events occurred during ATS sessions.
Conclusions: ATS significantly improves asthma control and quality of life in patients with asthma. Whether ATS may
improve lung function remains to be shown.
Trial registration: ClinicalTrials.gov NCT02501824. Retrospectively registered on 8 July 2015.
Keywords: Anthroposophic therapeutic speech, Asthma, Breathing, Lung function, Quality of life
Background
Breathing retraining techniques have received increased
attention in the management of asthma, because there is
growing evidence for the safety and usefulness of such
methods. The Global Initiative for Asthma (GINA) reports
evidence level B for the breathing techniques adjuvant to
pharmacotherapy [1], and the British Guideline on the
Management of Asthma similarly states a level of
recommendation A for such techniques to improve quality
of life, reduce symptoms and reduce bronchodilator use [2].
Physiotherapist-guided breathing programmes such as
the Papworth method and the Buteyko method are the
most systematically investigated and also yield the best
evidence for effectiveness. The breathing programmes
aim to reduce hyperventilation, strengthen nasal and
diaphragmatic breathing, and reduce respiratory rate
and minute volume [3]. The most consistent results
favouring the intervention group have been found for
quality of life (e.g. SF-36) and asthma related quality of
life (e.g. Asthma Quality of Life Questionnaire, AQLQ)
as well as in Asthma Control Test (ACT) scores [4]. So
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far, there is no convincing evidence for significant im-
provements in pulmonary function resulting from
breathing interventions [2, 4]. However, an innovative
recent study investigating physiotherapy-based breathing
retraining demonstrated significant effects for end tidal
CO2, breathing rate and predicted forced expiratory vol-
ume for the experimental group versus no additional
treatment. The effects continued for 5 months, during
which time patients practised the breathing behaviour
learned in the training programme [5]. So far, there is in-
sufficient evidence for the efficacy of breathing methods
in the context of yoga, biofeedback and respiratory
muscle training [2, 4, 6, 7].
Active breathing modulation techniques are frequently
considered to be complementary medicine (CM) [6].
Even if such techniques are often not included in con-
ventional asthma management plans, patients may take
a different perspective, since the prevalence of CM in
the treatment of asthma is 20–30% among adults and
50–60% for children, even if rigorous estimates are ap-
plied [8]. Breathing exercises have been found to be the
most commonly used CM method [9].
Among holistic CM systems, anthroposophically ex-
tended medicine (AEM) is a well-integrated approach
practised in both inpatient and outpatient settings by
medical doctors and certified therapists. Currently, an
AEM service is available in more than 50 countries [10].
AEM provides holistic health care, i.e. combining main-
stream medicine with specific therapies. Prospective co-
hort studies have shown that it improves symptoms and
the quality of life of patients with chronic diseases [11,
12]. Anthroposophic therapeutic speech (ATS) is one of
the arts therapies, which aims at improving respiratory,
vocal and articulatory functions by applying sounds and
syllabic rhythm in combination with speaking poetry.
Here, old forms of rhythmic verse, like Greek hexameter,
have been shown to improve cardiorespiratory inter-
action and to evoke a calm and relaxed state of mind
[13, 14]. ATS has been used in AEM for over 80 years
and is provided by certified therapists in therapy centres
and clinics for anthroposophic medicine [10]. The
method has been used for many years as breathing
retraining in the treatment of asthma.
Our study is the first to investigate the effects of ATS in
patients with asthma in real-life outpatient settings. Based
on our clinical experience, we assumed that 3 months of
ATS including weekly training with a therapist and practis-
ing at home, would improve quality of life, asthma control
and lung function. In particular, the following hypotheses
were tested: (i) ATS improves asthma control and quality of
life in patients with asthma, (ii) ATS improves relevant pa-
rameters of pulmonary function in patients with asthma
and (iii) ATS reduces the application of reliever medications
(used as needed) in patients with asthma.
Methods
Study design
The study was carried out as a randomised controlled
multi-centre two-period crossover exploratory clinical trial
conducted at three centres in Switzerland and Germany
between October 2010 and August 2014. The trial was ap-
proved by the relevant ethical committees (Bern KEK 115/
10, Basel EKBB 35/11 and Berlin KEK 115/10). It was
registered post-interventions on 8 July 2015 on
clinicaltrials.gov (NCT02501824), because when the trial
was planned, the registration of non-pharmacological
trials was not required in Switzerland. A Consolidated
Standards of Reporting Trials (CONSORT) checklist is
included in Additional file 1.
Participants were randomly assigned in a 1:1 allocation
ratio to either receive 11 ATS sessions (one per week
intended) or to wait (control). The patients were diagnosed
and informed about the trial by the participating pneumol-
ogists. Patients interested in participating were referred to
the study therapist, to receive and discuss an information
sheet prior to providing written informed consent. The ori-
ginal study protocol included 11 conversation sessions with
the same therapist as a control intervention. The protocol
had to be modified after the third patient, as the patients
were not complying with the 11 sessions of the control
intervention, i.e. the conversations with the therapist. The
conversation sessions were replaced by a waiting phase
after approval from the ethical committee.
Blinding of the patients, therapists and physicians was
not possible due to the nature of the intervention. Blind-
ing of the statistician, who was part of the study team
and had access to the primary data, was not attempted.
Participants
Inclusion criteria were: 12 years or older, bronchial asthma
for at least 1 year, inhaled a β2 agonist more than once per
week and signed an informed consent form (or signed by a
parent for a minor) prior to the beginning of the interven-
tions. The diagnosis of asthma was made according to the
current American Thoracic Society/European Respiratory
Society recommendations [15]. Asthma severity had to be
at least mild, persistent and not completely controlled. The
diagnosis of asthma and exclusion of any other relevant
airway disease was done by a respiratory physician.
Exclusion criteria were: severe systemic illness, coronary
heart disease, severe chronic obstructive pulmonary disease,
insufficient general condition to participate in an active
therapy, pregnancy and current use of oral corticosteroids.
Interventions
Interventions were administered in an outpatient centre
(group practice: Therapeutikum Bern, Switzerland) and in
the pneumology units of two clinics for mainstream
medicine and AEM (Klinik Arlesheim, Switzerland and
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Gemeinschaftskrankenhaus Havelhöhe Berlin, Germany).
Each participant was seen one-to-one by the same certified
therapist for all training sessions and asked to practise for
at least three times a week. ATS therapists have received
full-time training in speech, drama and ATS for 4 years.
The training programme for each patient consisted of
10 frequently applied ATS exercises, which comprise
spoken sound combinations of syllables (e.g.
“Wwwwww-T” / “OM”) and rhyme (e.g. six lines of hex-
ameter in German), adapted to the patient’s individual
needs.1 The exercises have to be performed full-toned
with the following aims: (a) extending and deepening res-
piration and making respiration rhythmical, (b) reducing
hyperventilation, (c) improving sensations of stiffness and
congestion in the chest and diaphragm and (d) opening
airways by means of sound (e.g. syllables consisting of the
vowel “A” together with consonants like “B”, “D” and “C”).
Outcome parameters
The primary outcome measures were changes in AQLQ
scores [16] and spirometry parameters: forced expiratory
volume in 1 s (FEV1), forced vital capacity (FVC) and
the ratio FEV1/FVC. The AQLQ was administered by
the study therapists. Spirometry was measured in all
centres by a pneumologist prior to the first phase, at
crossover and after the second phase of the study.
Secondary outcomes were changes in inhaled gluco-
corticoids (in μg) per week, ACT score [17], peak flow
and the number of days without asthma exacerbations
per week. Participants kept daily diaries to record morn-
ing and evening peak expiratory flow measurements,
medication use, exacerbations, worsening of condition,
perceived pollen load, infections and holidays. The ACT
questionnaire was filled out monthly.
To calculate changes in the outcome parameters, base-
line values (i.e. measurements before a phase for primary
outcomes or ACT and average values of the first 2 weeks
of a phase for secondary outcomes) were subtracted
from the values at the end of each phase. This was justi-
fied by the high correlation (>0.5) between baseline and
outcome values [18].
Sample size
No study on ATS in asthma patients was available as a basis
to determine the sample size. We assumed a median effect
size (d = 0.5), and set a power of 0.8 and α= 0.05. For paired
data, n = 34 would be sufficient to detect a significant differ-
ence. Allowing for dropouts, we determined a sample size of
50 patients to finally reach n ≥ 34 for data analysis.
Randomisation
The digits of π were used to generate the random alloca-
tion sequence, starting with the 151st digit (even digits
stood for ATS and odd digits for waiting in the first
phase). The random allocation sequence was generated
by the statistician and managed by one therapist. Eligible
patients were assigned to the two groups prior to the
first information session with the therapist at which the
informed consent had to be signed. The therapists en-
rolled the patients.
Statistical methods
Analyses were performed using IBM SPSS Statistics for
Windows, Version 23.0 (IBM Corp., Armonk, NY, USA).
Normality of within-patient differences was verified
using the Shapiro–Wilk test. p < 0.05 was considered
statistically significant, and since this was an exploratory
study, no adjustment for multiple comparisons was cal-
culated. All tests were two-tailed. When within-patient
differences were normally distributed (as for most pri-
mary endpoints), the dependent t-test was used to com-
pare the two phases. For non-normally distributed
endpoints, the Wilcoxon signed-rank test was applied.
Missing data were not estimated.
Additionally, the same analysis was performed includ-
ing only patients for which all data were available and
whose medication intake was in accordance with the
study protocol (a per protocol analysis).
Results
Patient characteristics
Altogether, 63 patients with asthma were randomised, of
which 56 were enrolled (28 in Arlesheim, 20 in Berlin and
8 in Bern) and 49 (87.5%) completed the study (Fig. 1).
The baseline characteristics of the participants are shown
in Table 1. The patients’ median FEV1/FVC was 69% and
the ACT score 18 points. The median study duration per
patient from the initial to the final medical examination
was 182.5 days (interquartile range, IQR 167–219 days).
Effectiveness
Table 2 presents the treatment effects according to the
intention-to-treat analysis. The AQLQ score increased by
0.63 points after ATS compared to 0.07 points after wait-
ing, resulting in a 0.56-point difference between the two
phases. Statistically significant differences between ATS
and waiting were found for the overall score and the do-
main scores for symptoms, activity limitation and emo-
tional function. No significant differences were observed
in spirometry parameters, inhaled glucocorticoids, peak
flow and days without asthma exacerbation per week. The
ACT score rose by 1.57 points after ATS compared to
−0.51 points after waiting, adding up to a statistically sig-
nificant 2.09-point difference between the two phases.
In addition, a per protocol analysis with 24 patients was
performed, with similar results as in the intention-to-treat
analysis. Statistically significant differences between the two
phases were observed for the overall AQLQ score, activity
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limitation and emotional function (p = 0.015, p = 0.007 and
p = 0.025, respectively). No significant changes were found
in spirometry parameters (p(FEV1) = 0.631, p(FVC) = 0.961
and p(FEV1/FVC) = 0.889). The changes in the ACT score
were no longer significant (p = 0.121).
There were indications for trend and/or carryover effects.
In the group who waited during the first phase, a slight im-
provement in the overall AQLQ score and symptoms was
noted during that phase (Fig. 2). In the other group, who
first received ATS and then entered the waiting phase, the
parameters (overall AQLQ score and all domain scores) did
not return to the initial values.
Safety
No serious adverse events occurred during ATS sessions
or were reported by patients in the following sessions.
Fig. 1 Flow of participants in the study. ATS anthroposophic therapeutic speech
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However, 15 patients reported 22 minor adverse events
to the therapists, which included difficulties in practising
at home (9) (e.g. “I can’t practise when my partner is
there”), worsening of condition during the waiting phase
(5), high effort required to participate in the study (2),
ATS phase too short to profit from the therapy (2),
difficulty in connecting with the German language (1),
hoarseness (1), headache (1), and cramping in the abdo-
men during one exercise (1). The therapists noted 20
minor adverse events in 14 patients. These included
difficulties in performing the exercises (8), coughing (5)
or a tickle in the throat (4), and hoarseness (3).
Discussion
Of our three hypotheses, one was confirmed: ATS signifi-
cantly improved asthma control and quality of life in pa-
tients with asthma. The AQLQ score rose by 0.56 points,
0.5 points being considered the minimal clinically import-
ant difference [19]. The ACT score rose by 2.09 points. We
were not able to demonstrate that ATS improved the
Table 1 Baseline characteristics of the trial participants
Characteristics ATS/waiting
(n = 32)
Waiting/ATS
(n = 24)
Total
(n = 56)
Age, years, median (IQR) 50 (42–62) 49 (40–60) 49 (42–61)
Female, no. (%) 21 (66) 17 (71) 38 (68)
Body mass index, kg/m2, median (IQR) 24 (22–26) 22 (20–25) 23 (21–25)
Asthma Control Test,* median (IQR) 18 (14–22) 18 (15–21) 18 (15–22)
Asthma Quality of Life Questionnaire,† median (IQR) 4.5 (3.6–5.3) 4.7 (3.8–5.2) 4.6 (3.7–5.2)
Lung function, median (IQR)
FEV1, L 2.72 (2.02–3.38) 2.43 (2.02–3.05) 2.68 (2.03–3.20)
FEV1, % 88 (72–105) 85 (70–102) 85 (71–103)
FVC, L 3.54 (3.15–4.84) 3.43 (2.87–4.45) 3.52 (3.10–4.78)
FEV1/FVC, % 69 (63–77) 69 (62–75) 69 (62–76)
ATS Anthroposophic Therapeutic Speech, FEV1 forced expiratory volume in 1 s, FVC forced expiratory vital capacity, IQR interquartile range
*Range 5–25, higher scores indicate less severe disease, score >19 indicates well-controlled asthma
†Range 1–7, higher scores indicate less impairment
Table 2 Treatment effects (intention-to-treat analysis)
Outcome ATS, mean (SD)
(n = 49)
Waiting, mean (SD)
(n = 49)
Effect size, Cohen’s d (95% CI) p value
Asthma Quality of Life Questionnaire
Overall 0.63 (0.67) 0.07 (0.63) 0.86 (0.43 to 1.28) 0.001
Symptoms 0.60 (0.87) 0.03 (0.72) 0.71 (0.28 to 1.12) 0.006
Activity limitation 0.74 (0.76) 0.10 (0.76) 0.84 (0.41 to 1.25) 0.001
Emotional function 0.57 (0.85) 0.05 (0.91) 0.58 (0.17 to 0.99) 0.013
Environmental exposure 0.56 (1.03) 0.15 (0.84) 0.43 (0.02 to 0.84) 0.079
Lung function
FEV1, L − 0.01 (0.32) 0.05 (0.29) − 0.18 (− 0.58 to 0.23) 0.471
FVC, L 0.02 (0.33) 0.03 (0.30) − 0.06 (− 0.46 to 0.35) 0.805
FEV1/FVC, %‡ 0.00 (0.09) 0.01 (0.10) −0.01 (− 0.41 to 0.40) 0.385
Inhaled glucocorticoids, μg per week†‡ 6.96 (189.08) −8.35 (168.63) 0.09 (−0.31 to 0.48) 0.581
Asthma Control Test‡ 1.57 (4.06) −0.51 (3.78) 0.53 (0.12 to 0.94) 0.048
Peak flow (morning), L/min‡ 8.27 (46.30) 5.42 (44.18) 0.06 (−0.35 to 0.47) 0.519
Peak flow (evening), L/min‡ 9.24 (50.66) 9.71 (44.19) −0.01 (− 0.42 to 0.40) 0.943
Days without asthma exacerbation per week‡ 0.20 (1.27) 0.05 (0.98) 0.12 (−0.29 to 0.53) 0.758
Changes from the beginning to the end of the respective phase are presented. Dependent t-test was used if not stated otherwise
ATS anthroposophic therapeutic speech, FEV1 forced expiratory volume in 1 s, FVC forced expiratory vital capacity, SD standard deviation
‡Wilcoxon signed-rank test
†In reliever medication
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parameters of the pulmonary function tests or reduced the
use of reliever medications in our study population of out-
patients during the 11 weeks of treatment.
The baseline median ACT score of 18 points (<19) in our
population as well as the median FEV1/FVC of 69% (<75%)
indicated that asthma was not well controlled by our partic-
ipants [20]. After ATS, the median ACT score rose to 20.09
points, corresponding to well-controlled asthma, even if the
minimal clinically important difference is a change of 3
points [21]. This is consistent with the observations of pa-
tients, physicians and therapists, who expressed satisfaction
with the clinical improvement after ATS.
All patients were regularly seen by a pneumologist and
took conventional medication. However, we observed a
low adherence to medication in some patients. These pa-
tients were excluded in a subsequent per protocol analysis,
which gave similar results as the primary analysis. Low ad-
herence has been observed in other investigations, too
[22]. A population-based study showed that CM use was
associated with poor asthma control that was independent
of the level of intake of controller medication [9]. Taken
together, these results may suggest that the patients in our
study represent a special group of asthma patients who
are suffering from difficult-to-control asthma and ready to
learn active breathing retraining.
It is known that objective measures in the treatment
of asthma only weakly to moderately correlate with how
patients actually feel and are able to function in daily
life. Thus, improvements in health-related quality of life
may be rated more important than spirometry values,
and they may be complementary outcomes [23].
The systematic review by Burgess et al. [6] identified only
one trial in which pulmonary function changed during
breathing retraining [5]. In this trial, the patients learned
breathing retraining techniques in 12 individual sessions
(three per week) and practised frequently at home (two or
three times per day for 20 min) for 5 months. Other trials
used fewer training sessions and a shorter training practice
time of, e.g., 10 min/day. Those trials showed no improve-
ment in pulmonary function. Responses in quality of life
and asthma control parameters may, thus, be attained earl-
ier than for pathophysiological outcomes.
Whether ATS improves lung function remains to be
shown. ATS uses elements of language readily available
to every speaking person and modifies the depth, rhythm
and duration of exhalation by means of sound and
Fig. 2 Box plots of overall AQLQ and ACT scores. Data at baseline, after waiting phase and after ATS, subdivided into the two groups are shown.
Circles represent outliers. Spirometry parameters are not displayed, since no significant changes were observed. ACT Asthma Control Test, AQLQ
Asthma Quality of Life Questionnaire, ATS anthroposophic therapeutic speech
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syllable combinations. The awareness of patients during
therapy is shifted from respiration to voice and articula-
tion. Asthma impairs perceptual voice quality, maximum
phonation time, frequency and amplitude perturbation
parameters [24]. Thus, it is not surprising that patients
receiving ATS appreciate the voice-work as an important
part of ATS.
Keeping in mind that we performed a total of 539 in-
dividual therapy sessions in the trial, side effects oc-
curred only rarely. The physical symptoms seen, e.g.
coughing, may occur in all voice therapies and could be
dealt with accordingly. Adverse events during the wait-
ing phase were not systematically recorded, and thus a
comparison between the two phases was not possible.
Some patients’ asthma symptoms increased during spring
due to the higher pollen count or during winter due to infec-
tions of the upper respiratory tract. We recruited patients
during all seasons to distribute these influences evenly.
In planning this real-life study, we faced several meth-
odological issues. Blinding of the patients was not pos-
sible, since ATS requires the active participation of the
patients, which is a limitation of this study. Many patients
were reluctant to be randomly assigned to a control group
without receiving the test therapy, i.e. speech therapy.
Thus, a parallel-group design with sufficient power was
not feasible. Performing a crossover trial allowed all par-
ticipants to receive therapy, though dropouts, trends and
carryover effects would represent general difficulties in
the analysis. In this trial, dropouts only occurred in the
ATS phase, mostly due to reasons unrelated to the therapy
(e.g. infection or a leg fracture, Fig. 1). Randomisation
took place before consent to participate in the study was
received, and some patients allocated to waiting in the first
phase decided not to participate.
A trend effect was visible during the first phase in the
waiting group in some outcomes (e.g. overall AQLQ
score). Context and meaning effects (e.g. patients’ expecta-
tions and monitoring of peak flow and medication intake)
may have contributed to this finding. However, the study
design does not allow us to discern if this effect continued
during the second phase. In the group performing ATS
first, AQLQ scores did not drop significantly during the
subsequent waiting phase (Fig. 2), suggesting there was a
considerable training effect (carryover).
On average, the patients participating in the trial experi-
enced a positive outcome in asthma-related quality of life
and asthma control, which continued after the crossover
to the waiting phase. However, this carryover effect ham-
pered our statistical analysis of the trial and reduced the
practical advantages of the crossover study design. Thus,
compliance and trial-design conflicts should be considered
carefully in future studies of ATS. Researchers may also
consider a longer treatment period and more intense
regular practice at home.
Conclusions
Breathing exercises are the most commonly used CM
method for patients with asthma. In this randomised
controlled crossover trial, we were able to demonstrate
that ATS significantly improves asthma control and
quality of life in patients with poorly controlled asthma.
The side effects of ATS were only minor and occurred
rarely. Whether ATS also improves lung function re-
mains to be shown. In future trials, a longer treatment
period and more intense regular practice at home may
be considered.
Endnotes
1Details of the exercises are available from the authors.
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